key: cord-0933095-8mvbv2vw
authors: Damin, F.; Galbiati, S.; Gagliardi, S.; Cereda, C.; Dragoni, F.; Fenizia, C.; Savasi, V.; Sola, L.; Chiari, M.
title: CovidArray: a microarray-based assay with high sensitivity for the detection of SARS-CoV-2 in nasopharyngeal swabs
date: 2021-01-26
journal: nan
DOI: 10.1101/2021.01.21.21250281
sha: cbfc1c6bd39f8e98d3d42201daa55ba48b3b60c2
doc_id: 933095
cord_uid: 8mvbv2vw

Background: A new coronavirus (SARS-CoV-2) caused the current Covid-19 epidemic. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) is used as the gold standard for clinical detection of SARS-CoV-2. Under ideal conditions RT-qPCR Covid-19 assays have analytical sensitivity and specificity greater than 95%. However, when the sample panel is enlarged including asymptomatic individuals, the sensitivity decreases and false-negative are reported. Moreover, RT-qPCR requires up to 3-6 hours with most of the time involved in RNA extraction from swab samples. Methods: We introduce CovidArray, a microarray-based assay, to detect SARS-CoV-2 markers N1 and N2 in the nasopharyngeal swabs. The method is based on solid phase hybridization of fluorescently labelled amplicons upon RNA extraction and reverse transcription. This approach combines the physical-optical properties of the silicon substrate with the surface chemistry used to coat the substrate to obtain a diagnostic tool of great sensitivity. Furthermore, we used an innovative approach, RNAGEM, to extract and purify viral RNA in less than 15 minutes. To validate the CovidArray results, we exploited the high sensitivity of the droplet digital PCR (ddPCR) technique. Results: We correctly assigned 12 nasopharyngeal swabs, previously analyzed by RT-qPCR. Thanks to the CovidArray sensitivity that matches that of the ddPCR, we were able to identify a false-negative sample. Conclusions: CovidArray is the first DNA microarray-based assay to detect viral genes in the swabs. Its high sensitivity and the innovative viral RNA extraction by RNAGEM allows to reduce both the amount of false negative results and the total analysis time to about 2 hours.

In December 2019, an unexplained acute respiratory disease, Covid-19, emerged in Wuhan, China (1) . It was immediately determined that the disease's cause was a novel coronavirus named SARS-CoV-2 (2) . Since virus identification and sequencing in early January 2020 (3), the primary approach for detecting viral RNA in respiratory specimens was the reverse transcriptionquantitative polymerase chain reaction (RT-qPCR) (4, 5) . The RT-qPCR, initially used to confirm symptomatic patients' diagnosis, was increasingly used to screen asymptomatic contacts and subjects at risk. Several RT-qPCR assays have been developed and recommended by the World Health Organization, the United States Centers for Disease Control and Prevention, the Chinese Center for Disease Control and Prevention, as well as by private companies (6, 7) . In the absence of specific therapeutic drugs for Covid-19, it is essential to detect the disease at early stage and immediately isolate the infected person from a healthy population. RT-qPCR Covid-19 assays have analytical sensitivity and specificity greater than 95% (8) . However, this number refers to tests validated under ideal conditions with hospital samples containing viral loads higher than those from asymptomatic individuals. When the sample panel is enlarged to include asymptomatic individuals, the sensitivity decreases and false-negative rates between 2% and 33% (8) are reported. In the current emergency, individuals with Covid-19 that are not identified and quarantined represent a transmission vector for a larger amount of the population given the highly contagious nature of the virus. Failures in SARS-CoV-2 detection may be related to multiple preanalytical and analytical factors, such as lack of standardization for specimen collection, poor storage conditions before arrival in the laboratory and lack of specialized personnel for collection and analysis of the samples.

Furthermore, poorly validated assays, contamination during the procedure, insufficient viral specimens or viral load contribute to results' uncertainty. The variable viral load along the disease' incubation period, or the presence of mutations and PCR inhibitors (9, 10) also impact the diagnosis. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01. 21.21250281 doi: medRxiv preprint In addition, shortage of reagents is also greatly contributing to spread the disease by delaying the Covid-19 diagnostics and reducing the number of tests available. Many regions around the world have experienced a shortage of laboratory-based molecular-assay tests. Executing a test requires about 20 different reagents, consumables, and other pieces of equipment. Of those materials, major shortages have been reported in RNA-extraction kits (11) .

We propose an approach to detect SARS-CoV-2 endowed with high sensitivity, accuracy, and multiplexing capability based on microarray technology, named CovidArray. The method is based on solid phase hybridization of fluorescently labelled amplicons upon RNA extraction, and reverse transcription. Essential features of this system, already successfully applied in liquid biopsy and prenatal diagnosis (12) (13) (14) , are: i) the use of crystalline silicon chips coated by a 100 nm thermally grown silicon dioxide (SiO2) layer to enhance fluorescence signals (15) , and ii) the efficient surface chemistry used to bind to the substrate the oligonucleotide capture probes specific to the virus genes (16) . A three-dimensional coating made of copoly(DMA-NAS-MAPS), a copolymer known for its high binding capacity and low non-specific adsorption, was used (17) . To validate the microarraybased assay results, we exploited the high sensitivity of the droplet digital PCR (ddPCR) technique. ddPCR, whose limit of detection (LOD) has been shown by several works to be significantly lower than that of qPCR (18, 19) , is based on the principles of limited dilution, end-point PCR, and Poisson statistics, with absolute quantification as its heart (20) .

In this work, we followed the guidelines of the US Centers for Disease Control and Prevention (CDC) and the CDC 2019-Novel Coronavirus (2019-nCoV) RT-qPCR Diagnostic Panel (21) for the qualitative detection of RNA from SARS-CoV-2 in upper and lower respiratory specimens (such as nasopharyngeal or oropharyngeal swabs). The oligonucleotide primers and probes were selected from two virus nucleocapsid (N1 and N2) gene regions. An additional set of primers/probe to detect the human Ribonuclease P gene (RPP30) as a control of nucleic acid extraction in clinical specimens was also included in the panel. Many available commercial RT-qPCR kits employ multiplex system capable of detecting 2 or 3 different SARS-CoV-2 targets as well as an internal is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint control. Similarly, the CovidArray assay is able to perform a multiplex detection of the markers N1, N2 and RPP30, but, compared to the commercial RT-qPCR kits, our system has the additional potential to differentiate SARS-CoV-2 from other viral and bacterial respiratory tract infections simply by adding new primers and capture probes to the same array.

Another key improvement introduced by CovidArray is the faster analysis time. An important feature of a diagnostic assay during an outbreak is the overall execution time since a fast method would allow expanding the analytical throughput. The standard methodology for SARS-CoV-2 detection requires from 3 to 6 hours to run a test (22) with most of the time involved in RNA extraction from swab samples, with CovidArray the time required is reduced to about 2 hours.

Many commercial RNA extraction kits such as, for example, the Roche MagNA Pure 96 or the QIAGEN QIAcube kits have been validated for viral RNA extraction purpose (21) . Although the RNA isolation kits are easy to use in automated instruments, it might be necessary to use alternative approaches to extraction to expand the analytical capability in the case of an epidemic. In this work, we used an innovative single-tube approach to extract the viral RNA, by employing RNAGEM, a straightforward temperature-driven enzymatic method to extract RNA, commercially available by MicroGEM (MicroGEM UK Ltd, Southampton). The main advantages of using this extraction methodology are: i) minimal pipetting steps (manual or automated) leading to less contamination, virtually no loss of RNA and reduced amount of plastic consumables (pipette tips, tubes, etc; also in shortage during this pandemic), ii) no need of using a harsh chemical which eliminates the washing steps, iii) no need for further purification of the RNA for accurate RT-qPCR and qPCR analysis and iv) single-tube workflow that provides purified RNA in 10 minutes, v) extraction is conducted using a common laboratory thermocycler allowing to extract up to 96 samples simultaneously, vi) the manual steps can be automated easily by using any liquid handler.

Moreover, here we demonstrated that combination of single-tube extraction by RNAGEM with highly sensitive multiplex microarray substrate with optimal properties allow to reduce the number is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.21.21250281 doi: medRxiv preprint of PCR cycles from 40 to 25 and to lead to an overall increase in accuracy and a reduction in analysis time. Spotting is perfomed using a SciFLEXARRAYER S12 (Scienion, Berlin, Germany). InnoScan 710 (Innopsys, Carbonne, France) was used to scan the hybridized chips. Data intensities were extracted with the Mapix software and the data analysis was performed for each experiment.

A detailed description of the samples collection, RT-qPCR, Reverse Transcription and ddPCR and 2019-CoV Plasmid Controls is provided in the Online Supplemental Data.

The viral RNA was extracted by mixing 89.5 µL of the inactivated UTM (70°C for 1 h) containing a nasopharyngeal swab with 0.5 µL of RNAGEM enzyme (MicroGEM UK Ltd, Southampton) and 10 µL of 10X Blue Buffer. Subsequently, the extraction was conducted by incubating the reaction mix in a thermocycler at 75°C for 5 min and 95°C for 5 min.

. CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint In addition to the single amplification, we optimized a triplex PCR amplification in which the primers used for the N1, N2 and RPP30 amplification were mixed in the same PCR mixture.

The triplex PCR was performed in 20 µL of reactions containing 9 µL of diluted cDNA, 10 pmoles of each primer and 4 µL of 5X HOT FIREPol Blend Master Mix Ready to Load (Solis BioDyne).

Cycling conditions were as follows: 95 °C for 12 min; 25 cycles at 95°C for 20 s, 60°C for 30 s, 72°C for 30 s and finally 72°C for 7 min.

We selected three oligonucleotide sequences from the US CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-qPCR Diagnostic Panel corresponding to the two specific probes for the regions N1 and N2 of the virus nucleocapsid gene and to the human RPP30 gene. In addition, an oligonucleotide probe, not correlated to any viral or human sequences, was selected as negative hybridization control. Capture and control probes (reported in Supplemental Table 1) , amino modified at the 5' end, were dissolved in the printing buffer (150 mM sodium phosphate pH 8.5, 0.01% Sucrose monolaurate) to a concentration of 10 M and printed by a piezoelectric spotter, SciFLEX ARRAYER S12 (Scienion, Berlin, Germany) on silicon/silicon oxide slides coated with MCP-4 according to the protocol provided by the manufacturer. The spotting was performed at 20° C in an atmosphere of 60% humidity. After the spotting step the chips were incubated overnight and all residual reactive groups of the coating polymer were blocked as previously described (23) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 26, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 26, 2021. Firstly, it was demonstrated the correct assignment of samples previously assayed in the laboratory of Immunology at University of Milan (L. Sacco Hospital) with standard qPCR technology. In particular, five nasopharyngeal swabs (S1-S5) were analysed, four of which positive for the target N1 and N2 by RT-qPCR and one negative for both (S3). The four positive samples presented different viral loads resulting in different threshold cycles (Ct) in qPCR. In particular, for N1, the sample S1 crossed the threshold line at 20.00 cycles due to its high viral load; also sample S2 has a high viral load (22.00 cycles) while S4 and S5 have lower viral load and are detected at 38 and 36 cycles respectively (Table 1) .

. CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.21.21250281 doi: medRxiv preprint Figure 1B shows the results of the microarray analysis of the swab samples and the control NTCs for the SARS-CoV-2 markers (N1 and N2) and for the RPP30 positive control. Amplicons of N1, N2 and RPP30 were separately incubated on microarray chips. Three different silicon substrates were used to analyze one swab sample. As shown in Figure 1B is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.21.21250281 doi: medRxiv preprint fluorescence in the NTC subarrays is essential as it allows discriminating low-signal samples from background signals. The same samples were also assayed by ddPCR. Indeed, one of our samples (S3) from a patient negative according to the RT-qPCR assay, but with symptoms attributable to Covid-19, was found to be positive by CovidArray in agreement with ddPCR (N1=34.5 copies/µL; N2= 7.6 copies/µL). CovidArray matches the sensitivity of ddPCR (Figure 2) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.21.21250281 doi: medRxiv preprint Table2 Correspondence between RT-qPCR Ct and CovidArray a Cycle Threshold; b not applicable

Since the new SARS-CoV-2 emerged, researchers have struggled to develop highly sensitive molecular techniques to diagnose positive Covid-19 subjects effectively. According to the WHO and the Centre for Disease Control and Prevention (CDC), the gold standard for the diagnosis is qPCR. However, many studies have highlighted the presence of false negative results in RT-qPCR (24, 25) . Therefore, it is worthy to build-up novel robust methodologies that ensure high sensitivity useful not only for diagnostic purposes but also for the follow-up of patients and for monitoring of is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.21.21250281 doi: medRxiv preprint solution. Figure 3A shows the calibration curves for the region N1 and N2, respectively. The LODs (lowest concentration of detectable plasmid DNA) extrapolated for each marker are reported in Figure 3B . The determination of LOD is based on the equation: 3.3 σ/s where s is the slope of calibration curve and σ is the standard deviation of fluorescence background in the controlsample.

The LODs found with this system are 1.16 copies/L for the N1 and 0.81 copies/L for the N2, respectively. These LODs are comparable with those declared by the various manufacturers of kits for qPCR with the difference that the number of standard amplification cycles for those methods is 40 while, in our approach only 25 cycles are sufficient to detect the target genes. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint One of the peculiar features of microarray technology is its multiplexing capability. Different genes can be revealed in a single hybridization assay by spotting onto the microarray substrate different capture probes specific to the target. In this work, we exploited the multiplexing capability of the CovidArray to detect the presence of the N1, N2 markers of SARS-CoV-2 and the RPP30 control gene on a single silicon chip in a single hybridization assay. We performed a triplex PCR, amplifying simultaneously the genes N1, N2 and RPP30 using the cDNA produced by reverse transcription of the RNA extracted from the same 5 nasopharyngeal swabs as reported in the "Materials and Method" section. The triplex PCR was hybridized with the probes spotted on the same substrate. The simultaneous appearance of fluorescence signals on the subarrays corresponding to the N1 and N2 regions confirmed the positivity of the sample. The fluorescence signal of the RPP30 subarray was also detectable. In Figure 4B five triplex PCR' hybridization results corresponding to the S1-S5 samples are shown. The NTC does not show significant fluorescence. In Figure 4C the histogram of fluorescence intensity indicates that the samples S1 and S2 have a higher fluorescence intensity confirming the higher viral load detected by the single-PCR CovidArray. Sample S3 which was considered negative by the RT-qPCR technique shows a weaker but detectable signal in agreement with ddPCR and single-PCR CovidArray. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

In summary, we describe a novel microarray platform, CovidArray, for the specific and sensitive detection of SARS-CoV-2 in nasopharyngeal swabs. This approach combines the physical-optical properties of the silicon substrate with the surface chemistry used to bind to the substrate the oligonucleotide capture probes specific to the virus' genes to obtain a diagnostic tool of great sensitivity. In agreement with ddPCR, we correctly assigned 12 nasopharyngeal swabs of different origins. Thanks to the lower limit of detection of CovidArray, we identified a false-negative sample.

Another feature of our system, also due to the high sensitivity of the CovidArray, is the decrease of the number of PCR cycles required to detect the viral markers which, in turn, leads to a significant . CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.21.21250281 doi: medRxiv preprint reduction of the analysis time. A further contribution to speeding up the diagnostic assay is the use of an alternative method for extracting the viral RNA from clinical samples. In this work, we used an innovative approach, RNAGEM, commercially available by MicroGEM, to extract and purify viral RNA in less than 15 minutes. The total time required for the molecular test can thus range from about 3-6 hours of a standard process to about 2 hours with the CovidArray method.

Moreover, RNAGEM provides an alternative to commercial RNA extraction kits that may undergo a shortage due to their massive use during the pandemic. Furthermore, in this work we have exploited the multiplexing capability of the microarray technology, to detect the presence of viral markers and the control sequence in a single assay. Finally, it is worth noticing the versatility of this approach. In fact, CovidArray could potentially allow differentiating SARS-CoV-2 from other viral and bacterial respiratory tract infections by merely adding new primers and capture probes to the same array, becoming a promising diagnostic tool suitable for routine diagnosis of a wide range of respiratory diseases.

We are grateful to Riccardo Vago (Università Vita-Salute S. Raffaele, Milan) and Greta Bergamaschi (SCITEC CNR, Milan) for their contribution without which this work would have been much more difficult. We also thank Giuseppina Sannino (MicroGEM UK Ltd, Southampton, United Kingdom) for her comments and for the supply of the RNAGEM Extraction Kit. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.21.21250281 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.21.21250281 doi: medRxiv preprint

A Novel Coronavirus from Patients with Pneumonia in China

The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2

Novel 2019 coronavirus genome

World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases

General Office of the National Health and Health Commission Office of the NA of TCM. Diagnosis and treatment of pneumonitis with a new type of coronavirus infection

nhc/1-clinical-protocols-for-the-diagnosis-and-treatment-of-covid-19-v7.pdf?sfvrsn=c6cbfba4_2

New novel coronavirus detection products approved by the National Medical Products Administration

United States Food and Drug Administration

False-negative results of initial RT-QPCR assays for COVID-19: a systematic review

Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19)

False-Negative Results of Real-Time Reverse-Transcriptase Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2: Role of Deep-Learning-Based CT Diagnosis and Insights from Two Cases

COVID-19: Overcoming supply shortages for diagnostic testing

Analysis of KRAS, NRAS and BRAF mutational profile by combination of in-tube hybridization and universal tag-microarray in tumor tissue and plasma of colorectal cancer patients

Microarray approach combined with ddPCR: an useful pipeline for the detection and quantification of circulating tumor DNA mutations

COLD-PCR and microarray: two independent highly sensitive approaches allowing the identification of fetal paternally inherited mutations in maternal plasma

Quantification of DNA and protein adsorption by optical phase shift

High sensitivity protein assays on microarray silicon slides

Characterization of a polymeric adsorbed coating for DNA microarray glass slides

ddPCR: a more accurate tool for SARS-CoV-2 detection in low viral load specimens

Sensitivity assessment of droplet digital PCR for SARS-CoV-2 detection

Centers for Disease Control and Prevention (CDC). CDC 2019-novel coronavirus

real-time RT-QPCR diagnostic panel

Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria

DNA microarray-based solid-phase PCR on copoly (DMA-NAS-MAPS) silicon coated slides: An example of relevant clinical application

Limits of detection of six approved RT-QPCR kits for the novel SARS-coronavirus-2 (SARS-CoV-2)

It is made available under a perpetuity.is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.21.21250281 doi: medRxiv preprint